Please login to the form below
Omotys
This page shows the latest Omotys news and features for those working in and with pharma, biotech and healthcare.
Latest news
-
Takeda-Affymax recall Omontys in US after deaths
Severe allergic reactions reported in kidney disease patients taking anaemia drug
More from news
Approximately 2 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Regeneron says antibody for COVID-19 could be ready this year
- Imperial College London to lead major coronavirus home testing programme
- Octapharma cleared to start phase 3 trial of Octagam in COVID-19
- Biogen delays filing of Alzheimer’s drug, which hits its share price
- Octapharma cleared to start phase 3 trial of Octagam in COVID-19
- Novartis to test canakinumab for COVID-19, as IL-6 trial disappoints
- ACCOMPLISH MEANINGFUL HCP ENGAGEMENT ONLINE
- New data backs remdesivir for COVID-19, but rings hydroxychloroquine alarm bell
- EPI-backed coronavirus vaccine from Novavax starts trials
- NICE approves Roche’s Tecentriq in TNBC after revising deal
- Effectively communicating in a public health crisis
- DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
PMHub
Real Science Communications
Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...
Latest intelligence
- ACCOMPLISH MEANINGFUL HCP ENGAGEMENT ONLINE
- The art of delivering valuable customer journeys aligned to your key messages in 2020...
- DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
- This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
- Why are new medicinal products denied reimbursement in France?
- Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...
Quick links
Infographics
